Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome.

@article{Dann2007RiskadaptedBR,
  title={Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome.},
  author={Eldad J Dann and Rachel Bar-Shalom and Ada Tamir and Nissim Haim and Menachem Ben-Shachar and Irit Avivi and Tzila Zuckerman and Mark H Kirschbaum and Odelia Goor and Diana Libster and Jacob M. Rowe and Ron Epelbaum},
  journal={Blood},
  year={2007},
  volume={109 3},
  pages={905-9}
}
Therapy of Hodgkin disease (HD) is designed to prolong progression-free survival and minimize toxicity. The best regimen to achieve this has not yet been defined. A total of 108 patients with newly diagnosed HD and adverse prognostic factors were prospectively studied between 1999 and 2004. They were assigned to therapy according to defined risk stratification. Patients were defined depending on the International Prognostic Score (IPS). Those with IPS of 3 or higher received 2 cycles of… CONTINUE READING
46 Citations
18 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 18 references

BEACOPP chemotherapy for advanced Hodgkin’s disease: results of further analyses of the HD9- and HD12trials of the German Hodgkin Study Group (GHSG) [abstract

  • V Diehl, C Brillant, J Franklin
  • Blood .
  • 2004

Similar Papers

Loading similar papers…